Published in J Epidemiol Community Health on August 01, 2005
Moral imagination: the missing component in global health. PLoS Med (2005) 1.56
International cooperation and health. Part 2: making a difference. J Epidemiol Community Health (2005) 0.77
International research collaboration: the key to combating pulmonary vascular diseases in the developing world. Pulm Circ (2015) 0.75
International cooperation to promote advances in medicine. Ann Thorac Med (2008) 0.75
Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law (1996) 5.49
Health effects of climate change. JAMA (2004) 2.84
Public health in the new era: improving health through collective action. Lancet (2004) 2.45
Mortality certification and cause-of-death reporting in developing countries. Bull World Health Organ (2004) 1.34
Globalisation and public health. J Epidemiol Community Health (2002) 1.34
History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law J (2002) 1.25
The world's first international tobacco control treaty. BMJ (2002) 1.19
Competing interests: the importance of transparency. Eur J Public Health (2003) 0.85
Epidemiology in the 21st century. The challenges ahead. Eur J Public Health (2001) 0.84
United States wins more time to lobby against WHO diet plan. BMJ (2004) 0.83
Political interference in American science: why Europe should be concerned about the actions of the Bush administration. Eur J Public Health (2003) 0.82
Looking inside the tobacco industry: revealing insights from the Guildford Depository. Addiction (2004) 3.86
Unlocking the corporate documents of British American Tobacco: an invaluable global resource needs radically improved access. Lancet (2004) 3.76
Is the increasing policy use of Impact Assessment in Europe likely to undermine efforts to achieve healthy public policy? J Epidemiol Community Health (2010) 1.97
Corporate social responsibility and access to policy élites: an analysis of tobacco industry documents. PLoS Med (2011) 1.82
Tobacco industry influence on science and scientists in Germany. Am J Public Health (2005) 1.80
What is known about tobacco industry efforts to influence tobacco tax? A systematic review of empirical studies. Tob Control (2012) 1.67
The freeze on mass media campaigns in England: a natural experiment of the impact of tobacco control campaigns on quitting behaviour. Addiction (2014) 1.60
"The law was actually drafted by us but the Government is to be congratulated on its wise actions": British American Tobacco and public policy in Kenya. Tob Control (2007) 1.47
"Working the system"--British American tobacco's influence on the European union treaty and its implications for policy: an analysis of internal tobacco industry documents. PLoS Med (2010) 1.47
Public health, corporations and the new responsibility deal: promoting partnerships with vectors of disease? J Public Health (Oxf) (2011) 1.42
International trade law, plain packaging and tobacco industry political activity: the Trans-Pacific Partnership. Tob Control (2013) 1.39
The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine (2013) 1.24
Transnational tobacco company interests in smokeless tobacco in Europe: analysis of internal industry documents and contemporary industry materials. PLoS Med (2013) 1.22
The world's first international tobacco control treaty. BMJ (2002) 1.19
Environmental Profile of a Community's Health (EPOCH): an instrument to measure environmental determinants of cardiovascular health in five countries. PLoS One (2010) 1.18
An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines. Health Aff (Millwood) (2011) 1.14
Effectiveness of tobacco control television advertising in changing tobacco use in England: a population-based cross-sectional study. Addiction (2014) 1.09
A critical evaluation of the volume, relevance and quality of evidence submitted by the tobacco industry to oppose standardised packaging of tobacco products. BMJ Open (2014) 1.05
The relation between intermittent dosing and adherence: preliminary insights. Clin Ther (2006) 1.04
Prevalence and determinants of smoking in Tirana city, Albania: a population-based survey. Public Health (2003) 1.02
Knowledge of the health impacts of smoking and public attitudes towards tobacco control in the former Soviet Union. Tob Control (2012) 0.97
The case for Ofsmoke: the potential for price cap regulation of tobacco to raise £500 million per year in the UK. Tob Control (2013) 0.95
Corporate philanthropy, political influence, and health policy. PLoS One (2013) 0.92
Advance market commitment for pneumococcal vaccines: putting theory into practice. Bull World Health Organ (2011) 0.92
Commentary: Winners and losers. Int J Epidemiol (2003) 0.86
Health in south-eastern Europe: a troubled past, an uncertain future. Bull World Health Organ (2004) 0.85
Health impacts of exposure to second hand smoke (SHS) amongst a highly exposed workforce: survey of London casino workers. BMC Public Health (2007) 0.83
How online sales and promotion of snus contravenes current European Union legislation. Tob Control (2012) 0.83
Tobacco industry attempts to influence and use the German government to undermine the WHO Framework Convention on Tobacco Control. Tob Control (2011) 0.83
Roll-your-own cigarettes in Europe: use, weight and implications for fiscal policies. Eur J Cancer Prev (2014) 0.82
Prediction of immunisation performance. Lancet (2013) 0.79
Inequalities in birth outcomes in Russia: evidence from Tula oblast. Paediatr Perinat Epidemiol (2005) 0.78
International cooperation and health. Part 2: making a difference. J Epidemiol Community Health (2005) 0.77
Tobacco control, the European Union and WHO. Two conventions provide opportunities to advance public health. Eur J Public Health (2002) 0.77
GAVI's Advance Market Commitment. Lancet (2010) 0.77
A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's Injection Safety Support. PLoS One (2010) 0.76